Study drug Lu AG13909 for congenital adrenal hyperplasia
Part of Genetic & congenital, Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This early study tests Lu AG13909 in people with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. It aims to see how the drug affects hormone levels and whether it is safe for different CAH hormone patterns.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed CAH type caused by 21-hydroxylase deficiency (often shown by a gene test or high 17-OHP blood level).
- Before taking your usual morning steroid dose, your 17-OHP blood level is more than 4 times the lab’s normal upper limit.
- Your body weight fits the study range: BMI between 18.5 and 40 (and at least 50 kg).
- You have been on a stable steroid (glucocorticoid) treatment for at least 1 month before screening; if you have the salt-wasting type, your mineralocorticoid is stable for at least 3 months (or at least 1 month for Part C).
- You are not pregnant and not breastfeeding.
- You haven’t had a known allergy or bad reaction to Lu AG13909.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medication for children with classic congenital adrenal hyperplasia (CAH). It aims to see if the drug helps better control hormone levels and reduce the need for high doses of current steroid medicines.
This study tests a new drug, atumelnant, for adults with classic congenital adrenal hyperplasia (CAH) caused by 21-OHD. It aims to see if it can help control hormone levels while allowing lower doses of current steroid medications.
This trial is creating a registry to track adult males with congenital adrenal hyperplasia (CAH) from 21-hydroxylase deficiency. It helps doctors learn more about the condition and how it changes over time.
This study tests a new medicine called crinecerfont in children under 4 years old with classic congenital adrenal hyperplasia (CAH), a condition where the body doesn't make certain hormones properly. Researchers want to learn if the medicine is safe and how it works in the body.
This study tests the long-term safety and effectiveness of the study drug atumelnant for people with congenital adrenal hyperplasia. It is for those who have already completed a previous atumelnant study and may benefit from continuing treatment.
This study helps young people with congenital adrenal hyperplasia (a condition affecting hormone production) move smoothly from pediatric to adult care. Researchers will develop and test a transition program with patients, caregivers, and healthcare providers to make this shift easier and safer.
Hear when a new Congenital Adrenal Hyperplasia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.